Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Alpha interferon: new associations in haematology/oncology. The Montpellier experience.

× No keyword cloud information.

22 in total

1. Alpha-interferon combination therapy of resistant myeloma.

Authors: R Alexanian; B Barlogie; J Gutterman
Journal: Am J Clin Oncol Date: 1991-06 Impact factor: 2.339

2. Natural interferon-alpha alone and in combination with conventional therapies in non-small cell lung cancer. A pilot study.

Authors: A Niiranen; L R Holsti; K Cantell; K Mattson
Journal: Acta Oncol Date: 1990 Impact factor: 4.089

3. A phase II study of days 1 and 8 cisplatin and recombinant alpha-2B interferon in advanced non-small cell lung cancer.

Authors: R Rosell; J Carles; A Ariza; I Moreno; N Ribelles; V Solano; I Pellicer; A Barnadas; A Abad
Journal: Cancer Date: 1991-05-15 Impact factor: 6.860

Review 4. Multidrug resistance in lymphomas.

Authors: A R Yuen; B I Sikic
Journal: J Clin Oncol Date: 1994-11 Impact factor: 44.544

5. Phase I study of the combination of alpha-2 interferon and cisplatinum.

Authors: C Walsh; J L Speyer; J Wernz; H Hochster; H Grossberg; A Chachoua; P Molinaro; M Meyers; R H Blum
Journal: J Biol Response Mod Date: 1989-02

6. Antiproliferative effects of interferons -alpha and -beta in combination with 5-fluorouracil, cisplatin, and cis- and trans-retinoic acid in three human lung carcinoma cell lines.

Authors: Y M Arbaje; G Bittner; J M Yingling; B Storer; J H Schiller
Journal: J Interferon Res Date: 1993-02

7. Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas.

Authors: M Kawano; T Hirano; T Matsuda; T Taga; Y Horii; K Iwato; H Asaoku; B Tang; O Tanabe; H Tanaka
Journal: Nature Date: 1988-03-03 Impact factor: 49.962

8. Human anti-mouse antibody response to the injection of murine monoclonal antibodies against IL-6.

Authors: E Legouffe; J Liautard; J P Gaillard; J F Rossi; J Wijdenes; R Bataille; B Klein; J Brochier
Journal: Clin Exp Immunol Date: 1994-11 Impact factor: 4.330

9. Treatment of malignant ascites due to recurrent/refractory ovarian cancer: the use of interferon-alpha or interferon-alpha plus chemotherapy in vivo and in vitro.

Authors: W R Bezwoda; T Golombick; R Dansey; J Keeping
Journal: Eur J Cancer Date: 1991 Impact factor: 9.162

10. Enhancement of cytotoxicity of cisplatin in vitro by recombinant human tumor necrosis factor and/or recombinant human interferon-alpha, -beta and -gamma.

Authors: C M Kim; W S Hong; J O Lee; T W Kang; Y W Kim; J K Song; T K Yun; C Y Kim
Journal: Jpn J Cancer Res Date: 1989-09